Newly funded drug linked to tachycardia, hep B and infection

The TGA has updated its safety advice for ibrutinib after reviewing latest research on the medicine’s risks and effects Ibrutinib, marketed in Australia as Imbruvica, is used for the treatment of certain types of blood cancers, including mantle cell lymphoma and Waldenstrom's macroglobulinaemia chronic lymphocytic leukaemia (CLL, which includes small lymphocytic lymphoma). Just last month

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Poll: What are your thoughts on direct supply?
Next Making the most of your intern year